Analysis of the prospects of platinib in the treatment of pulmonary leukocyte carcinoma with RET fusion gene

Pralsetinib is a targeted treatment drug that targets RET gene mutations and has shown remarkable results in the treatment of non-small cell lung cancer. This drug is especially widely used when dealing with patients with RET fusion genes. Pulmonary leukocyte carcinoma, as an important subtype of non-small cell lung cancer, includes a portion of patients with RET fusion genes. The formation of the RET fusion gene is the result of the fusion of the RET gene with other genes. This fusion leads to abnormal signaling in tumor cells, thereby promoting the growth and spread of tumors. Platinib has shown good therapeutic effects against this gene mutation.

In a clinical trial of advanced or metastatic RET mutation-positive non-small cell lung cancer, platinib showed encouraging results. Among treatment-naïve patients, the overall response rate reached 72%, with 5% of patients achieving complete response and 67% achieving partial response. The disease control rate is as high as 91%, and the clinical benefit rate has also reached 80%. In addition, platinib also significantly extended the survival time of patients, and its efficacy was durable and stable.

In addition to its remarkable efficacy, platinib also showed good tolerability. In clinical trials, the main side effects experienced by patients were mild discomfort, such as fatigue, nausea, and vomiting, and these side effects could be effectively controlled in most patients. In addition, platinib has a low incidence of serious adverse reactions during treatment, further demonstrating its safety.

However, there are potential risks and side effects with any medication. Therefore, when using platinib to treat pulmonary leukocyte carcinoma with RET fusion gene, doctors need to comprehensively evaluate the patient's condition and physical condition and formulate a personalized treatment plan. At the same time, patients also need to strictly follow the doctor's instructions, use medications correctly, and undergo regular examinations and evaluations to ensure the effectiveness and safety of treatment.